ProQR (PRQR) AI Stock Analysis

• Market Cap: $228.31M
• Dividend Yield: N/A
• Average Volume (3M): 247.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: 7.59%
• EPS Growth: -53.46%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 195,680
• 30 Day Avg. Volume: 247,961
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 4.84
• Enterprise Value/Gross Profit: 5.03
• Enterprise Value/Ebitda: -3.38
• 1Y Price Target: $8.20
• Price Target Upside: 277.88% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 49 Neutral
• Price Target: $2.00 ▼(-7.83% Downside)

ProQR's overall stock score is primarily driven by its strong revenue growth, which is offset by significant challenges in profitability and cash flow management. Technical indicators suggest a neutral to slightly bearish trend, while valuation metrics are unfavorable due to negative earnings and lack of dividends. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Positive Factors

Funding & Financial Stability

PRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.

Innovative Technology

ProQR with its Axiomer technology, finds itself in a unique position to exploit the EON based therapeutic editing for targeting genetically validated diseases with huge unmet need.

Partnerships

Partnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.

Negative Factors

Clinical Trial Timelines

The company has focused on the lead program AX-0810 for Primary Sclerosing Cholangitis (PSC) which is entering the Phase 1 study with the topline data expected in 4Q2025.

Market Competition

PRQR is one of just 3 public biotechs with ADAR capabilities, offering exposure to rare indications as well as highly prevalent cardiovascular and liver diseases.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on developing transformative RNA therapies for the treatment of severe genetic rare diseases. Founded in 2012 and headquartered in Leiden, Netherlands, the company is committed to creating innovative treatments for conditions that currently lack effective therapeutic options. ProQR's pipeline primarily targets genetic disorders affecting vision, such as Leber congenital amaurosis and Usher syndrome, by using its proprietary RNA technology platform.

How the Company Makes Money

ProQR Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, research funding, milestone payments, and royalties on product sales. Additionally, the company may receive grant funding from various institutions to support its research and development efforts. ProQR's financial performance largely depends on the successful advancement of its clinical pipeline and securing partnerships to commercialize its RNA therapy candidates.

ProQR Financial Statement Overview

Summary

ProQR demonstrates strong revenue growth, especially in the TTM period, but struggles with profitability. The balance sheet is stable with low leverage, yet negative return on equity and cash flow issues are concerning. The company needs to address profitability and cash flow to improve its financial health.

Income Statement

ProQR shows a significant increase in revenue over the years, with a notable revenue growth from 2023 to TTM (Trailing-Twelve-Months). However, the company struggles with profitability, as evidenced by negative EBIT and net income margins. The gross profit margin remains positive, indicating efficient cost management at the production level, but high operating expenses lead to negative net margins.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.21 in TTM, indicating manageable leverage. The equity ratio is 52.0%, suggesting a healthy proportion of equity financing. However, the company has consistently reported negative net income, impacting return on equity, which remains negative.

Cash Flow

ProQR's cash flow statement shows challenges in generating positive free cash flow, with negative free cash flow growth in TTM. The operating cash flow to net income ratio is negative, indicating issues in converting earnings into cash. Despite this, the company has managed to maintain liquidity through financing activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.91M	6.51M	4.04M	1.35M	0.00
Gross Profit	18.91M	6.38M	1.56M	1.35M	-2.19M
EBITDA	-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
Net Income	-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet
Total Assets	167.96M	137.88M	171.32M	209.58M	98.73M
Cash, Cash Equivalents and Short-Term Investments	149.41M	118.92M	94.78M	187.52M	75.84M
Total Debt	17.22M	19.73M	21.97M	60.37M	34.28M
Total Liabilities	79.40M	96.49M	106.21M	96.35M	42.18M
Stockholders Equity	88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow
Free Cash Flow	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
Operating Cash Flow	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
Investing Cash Flow	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
Financing Cash Flow	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 2.17 is below the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.07, and below the 200-day MA of 2.30, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.85 is Neutral, neither overbought nor oversold. The STOCH value of 25.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	61 Neutral	$342.04M	―	-91.44%	―	-2.04%	83.49%
SEER	60 Neutral	$135.35M	―	-25.25%	―	12.13%	-8.23%
Sector *	51 Neutral	$7.27B	-0.06	-62.84%	2.34%	15.16%	-2.86%
CGEN	51 Neutral	$140.27M	87.50	-35.66%	―	-48.16%	-97.37%
PRQR	49 Neutral	$228.31M	―	-75.99%	―	7.59%	-53.46%
SLN	49 Neutral	$238.06M	―	-99.23%	―	-40.10%	-16.60%